The Chemours Company

Fourth Quarter Earnings Presentation

February 24, 2016

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements as further described in the “Risk Factors” section of the information statement contained in the registration statement on Form 10 and other filings made by Chemours with the Securities and Exchange Commission. All information in this presentation speaks only as of February 24, 2016, and any distribution of this presentation after that date is not intended and will not be construed as updating or confirming such information. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles (“GAAP”) in the United States. These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted basic and diluted EPS and Adjusted EBITDA, which should not be considered as replacements of GAAP. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items, which are expected to be infrequent in occurrence, in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com.

Highlights

Delivered second half 2015 cost reductions of ~$100M

Announced additional portfolio actions

Achieved mechanical completion of Altamira TiO_2 facility

Realized working capital release of ~$399M

Enhanced liquidity position through agreement with DuPont and amended credit facility

Chemours™

4Q15 Overview

($ in millions unless otherwise noted)

Fourth Quarter Financial Summary

	4Q15	3Q15	Δ Seq.	4Q14	Δ Yr/Yr
Net Sales	$1,360	$1,486	($126)	$1,549	($189)
Adj. EBITDA	132	169	(37)	205	(73)
Adj. EBITDA Margin (%)	*9.7*	*11.4*	*(1.7)*	*13.2*	*(3.5)*
Net (loss) Income	(86)	(29)	(57)	79	(165)
Adj. Net Income	5	73	(68)	91	(86)
EPS[1]	($0.48)	($0.16)	($0.32)	$0.44	($0.92)
Adj. EPS[1]	$0.03	$0.40	($0.37)	$0.50	($0.47)
Free Cash Flow[2]	175	8	167	292	(117)

- Year-over-year, financial results lower primarily due to lower TiO_2 pricing and currency headwinds
- Sequentially, financial performance influenced by timing of Corporate & Other expenses and technology and licensing income

See reconciliation of non-GAAP measures in the Appendix

[1] Periods prior to 3Q15 are represented by pro forma basic and diluted EPS

[2] Defined as Cash from Operations minus cash used for PP&E purchases

Chemours™

2015 Overview

($ in millions unless otherwise noted)

Full Year Financial Summary

	2015	2014	Δ Yr/Yr
Net Sales	$5,717	$6,432	($716)
Adj. EBITDA	573	876	(303)
Adj. EBITDA Margin (%)	*10.0*	*13.6*	*(3.6)*
Net (loss) Income	(90)	400	(490)
Adj. Net Income	143	453	(310)
EPS[1]	($0.50)	$2.21	($2.71)
Adj. EPS[1]	$0.79	$2.50	($1.71)
Free Cash Flow[2]	(337)	(99)	(238)

- Double-digit Adjusted EBITDA margin despite currency headwinds and continued TiO_2 pricing pressures
- Cost reductions of ~$100M in the second half
  - ~$60M lower SG&A[3] and R&D
  - ~$40M lower COGS
- Working capital programs initiated to achieve long term productivity benefits
- Mechanical completion of Altamira

See reconciliation of Non-GAAP measures in the Appendix

[1]Periods prior to 3Q15 are represented by pro forma basic and diluted EPS

[2] Defined as Cash from Operations minus cash used for PP&E purchases

[3] Reflects exclusions to Adjusted EBITDA

Chemours™

Adjusted EBITDA Bridge: 4Q15 versus 4Q14

($ in millions)



- TiO_2 price down 14%
- Lower prices in Chemical Solutions

- Reduced fluoropolymer demand
- Timing of purchases and lower quota volumes of refrigerants

- Lower controllable costs
- Reduced raw material pricing

- Technology and licensing activity

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 4Q15 versus 3Q15

($ in millions)



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position

($ in millions)



- Quarter-end cash balance of $366M reflecting strong cash collections and lower inventory balances
- Net debt down to $3.6B
- Total Liquidity of ~$1B, including revolver availability of $625M[1]
- Restructuring payments of $27M in Q4, expected to be approximately $100 – 120M in 2016

[1] Based on Credit Agreement defined LTM Adjusted EBITDA, as amended February 2016, including pro forma adjustments, Senior Secured Net Debt/EBITDA of 1.5x

Chemours™

Liquidity Enhancement and Credit Facility Amendment

- **Enhanced liquidity from agreement with DuPont**
  - Extinguished cash and working capital true-ups contemplated in Separation Agreement with no payments
  - DuPont prepaid Chemours ~$190M for goods and services anticipated over the next 12 – 15 months
- **Additional flexibility from amendment of financial maintenance covenants in the revolving credit facility completed on February 19**
  - Changed leverage covenant to be calculated only on senior secured net debt basis, maximum cash offset of $400M to debt
  - Adjusted interest coverage ratio levels
  - Modified definition of Consolidated EBITDA to increase pro forma EBITDA add-backs for cost savings actions:
    - $125M through June 30, 2017
    - $80M through June 30, 2018
  - Deadline for permitted cost savings actions extended to June 30, 2017
  - Reduced revolver commitment by $250M; $750M total facility

Chemours™

Titanium Technologies Business Summary

Fourth Quarter Highlights

- Maintained double-digit EBITDA margin as cost reductions partially mitigated lower pricing
- Volume higher versus 4Q14, seasonally in line
- Currency headwinds persist
- Altamira mechanically complete
- Announced modest price increase, effective as contracts allow or after January 1, 2016, whichever comes first

Outlook Commentary

- Implementing pricing actions
- Altamira expected to begin commercial operations mid-year, providing cost benefits as ramp up begins
- Volume expected to be in line with regional GDP growth rates

Financial Summary *($ millions)*

	4Q15	3Q15	4Q14
Sales	$589	$616	$688
Adjusted EBITDA	$62	$80	$160
Adjusted EBITDA Margin (%)	*10.5*	*13.0*	*23.3*

Sales Drivers

	Yr/Yr % Δ
Price	(14)
Currency	(6)
Volume	6

See reconciliation of Non-GAAP measures in the Appendix

Fluoroproducts Business Summary

Fourth Quarter Highlights

- Seasonally lower volumes and customer inventory management
- Continued phase-out of older refrigerants resulted in higher prices on lower volumes
- Reduced polymer volume and pricing primarily driven by weak consumer electronics demand and impact of strong USD
- Sold non-core Chemoswed business

Outlook Commentary

- Market penetration and growth of Opteon™ product line expected to sequentially ramp up with strong second half anticipated
- Lower quotas for base refrigerants, partially offset by higher pricing
- Continued competitive polymer environment
- Cost reduction initiatives expected to mitigate competitive market dynamics

Financial Summary *($ millions)*

	4Q15	3Q15	4Q14
Sales	$515	$575	$575
Adjusted EBITDA	$80	$91	$73
Adjusted EBITDA Margin (%)	*15.6*	*15.8*	*12.7*

Sales Drivers

	Yr/Yr % Δ
Price	3
Currency	(6)
Volume	(7)

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Chemical Solutions Business Summary

Fourth Quarter Highlights

- Lower pricing driven by lower input costs
- Licensing income of $5M contributed to improved quarter performance
- Announced Beaumont Aniline plant sale to The Dow Chemical Company for $140M in gross proceeds

Outlook Commentary

- Strategic evaluation expected to be complete by mid-year
- Anticipate Aniline transaction to close in first quarter
- Cyanide production expected to run at full capacity

Financial Summary *($ millions)*

	4Q15	3Q15	4Q14
Sales	$256	$295	$286
Adjusted EBITDA	$16	$8	$1
Adjusted EBITDA Margin (%)	*6.3*	*2.7*	*0.3*

Sales Drivers

	Yr/Yr % Δ
Price	(7)
Currency	(3)
Volume	0

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Progress on Transformation Plan

($ in millions)

Cost Reduction Progress



Other Transformation Activity

- Portfolio Optimization
  - Announced sale of Aniline facility
  - Beginning shutdown process for Niagara RMS site
  - Implementing improvement plan for Methylamines business
  - Evaluating Sulfur and Clean & Disinfect
- Growing Market Positions
  - Opteon™ expected to ramp up in 2016
  - Mechanical completion of Altamira TiO_2 facility
  - On track for cyanides expansion
- Refocusing Investments
  - Reduce capex by ~$100M, on path to ~$350M in 2017
  - Evaluation for next tranche of Opteon™ capacity underway

Chemours™

2016 Outlook

- Full-year Adjusted EBITDA expected to be greater than 2015 level
- Reaffirm $200M in cost reduction target from transformation plan
- Full-year free cash flow anticipated to be modestly positive

Key Factors Influencing 2016 Performance:

Market Factors

- TiO_2 price
- Currency
- End-market demand

Chemours Initiatives

- Cost reductions
- Working capital productivity
- Ramp up in Opteon™
- Altamira start-up

2016 Adjusted EBITDA Expected to be Greater than 2015 with Modestly Positive Free Cash Flow

Chemours™

Appendix

GAAP Net (Loss) Income to Adjusted EBITDA and Adjusted Net Income Reconciliations

($ in millions unless otherwise noted)

	Three months ended December 31,		Year ended December 31,		Three months ended September 30,
	2015	2014	2015	2014	2015
Net (loss) income attributable Chemours	$ (86)	$ 79	$ (90)	$ 400	$ (29)
Non-operating pension and other postretirement employee benefit costs	(8)	4	(3)	22	(10)
Exchange losses (gains)	28	37	(19)	66	(44)
Restructuring charges	85	-	285	21	139
Asset impairments	3	-	73	—	70
Losses (gains) on sale of business or assets	9	(28)	9	(40)	-
Transaction, legal and other charges	17	-	17	—	-
Benefit from income taxes relating to reconciling items [1]	(43)	(1)	(129)	(16)	(53)
Adjusted Net Income	$ 5	$ 91	$ 143	$ 453	$ 73
Net income attributable to noncontrolling interests	-	-	—	1	-
Interest expense	53	-	132	—	51
Depreciation and amortization	66	72	267	257	70
All remaining provision for income taxes [1]	8	42	31	165	(25)
Adjusted EBITDA	$ 132	$ 205	$ 573	$ 876	$ 169
Adjusted earnings per share, basic	$ 0.03	$ 0.50	$ 0.79	$ 2.50	$ 0.40
Adjusted earnings per share, diluted	$ 0.03	$ 0.50	$ 0.79	$ 2.50	$ 0.40

[1] Total of (benefit from) provision for income taxes reconciles to the amount reported in the statement of operations for the years ended December 31, 2015, 2014 and 2013.

[2] On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted (loss) earnings per common share for the three-months and year ended December 31, 2014 were calculated using the shares distributed on July 1, 2015.

Chemours™

Segment Net Sales and Adjusted EBITDA (unaudited)

($ in millions unless otherwise noted)

	Three months ended December 31, 2015	Three months ended December 31, 2014	Year ended December 31, 2015	Year ended December 31, 2014	Three months ended September 30, 2015
SEGMENT NET SALES					
Titanium Technologies	589	688	2,392	2,937	616
Fluoroproducts	515	575	2,230	2,327	575
Chemical Solutions	256	286	1,095	1,168	295
Total Company	1,360	1,549	5,717	6,432	1,486
SEGMENT ADJUSTED EBITDA					
Titanium Technologies	62	160	326	723	80
Fluoroproducts	80	73	300	282	91
Chemical Solutions	16	1	29	17	8
Corporate & Other	(26)	(29)	(82)	(146)	(10)
Total Company	132	205	573	876	169
SEGMENT ADJUSTED EBITDA MARGIN					
Titanium Technologies	10.5%	23.3%	13.6%	24.6%	13.0%
Fluoroproducts	15.5%	12.7%	13.5%	12.1%	15.8%
Chemical Solutions	6.3%	0.3%	2.6%	1.5%	2.7%
Corporate & Other	0.0%	0.0%	0.0%	0.0%	0.0%
Total Company	9.7%	13.2%	10.0%	13.6%	11.4%

NOTE: In September 2015, the Company updated its definition of Adjusted EBITDA. All prior periods have been updated to reflect the current presentation.

Chemours™

Chemours™